CDC25C and prostate carcinoma: We found that EXO1 promoted BCL2, CDC25, and PCNA and inhibited BAX expression (Additional file 5: Fig. S5A–I), and further experiments showed that EXO1 inhibited apoptosis in prostate cancer cells.